Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 459
- Registration Number
- NCT02347332
- Locations
- 🇫🇷
Institut de Recherche Pierre Fabre, Toulouse, France
Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 17
- Registration Number
- NCT02266966
- Locations
- 🇫🇷
Centre d'Investigation Clinique (CIC), Toulouse, France
F17464 in Acute Schizophrenia Trial
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 158
- Registration Number
- NCT02151656
PERmixon® in LUTS Evaluation Study (PERLES)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 833
- Registration Number
- NCT02121613
Nicotine Patch - Bioequivalence Study
Phase 1
Completed
- Conditions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 74
- Registration Number
- NCT02089308
A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 1004
- Registration Number
- NCT02054338
Efficacy and Safety of V0111 Cream on Open Cracked Heel in Diabetic Patients With Polyneuropathy.
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 193
- Registration Number
- NCT02045199
Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia
Not Applicable
Completed
- Conditions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2014-04-15
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 40
- Registration Number
- NCT02005328
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2019-05-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 112
- Registration Number
- NCT01953003
- Locations
- 🇸🇬
Gleneagles Hospital, Singapore, Singapore
🇸🇬NUH, Singapore, Singapore
Bronchodilator Properties and Safety in Asthma
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 59
- Registration Number
- NCT01951222
- Locations
- 🇩🇪
CRO, Gauting, Germany
© Copyright 2024. All Rights Reserved by MedPath